Vuong Trieu - 22 Jan 2026 Form 4 Insider Report for Oncotelic Therapeutics, Inc. (OTLC)

Role: CHAIRMAN AND CEO, Director, 10%+ Owner
Signature: /s/ Vuong Trieu
Issuer symbol: OTLC
Transactions as of: 22 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 26 Jan 2026, 17:15:27 UTC
Previous filing: 19 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Trieu Vuong	CHAIRMAN AND CEO, Director, 10%+ Owner	29397 AGOURA RD SUITE 107, AGOURA HILLS	/s/ Vuong Trieu	26 Jan 2026	0001587074

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OTLC	Series A Convertible Preferred Stock	Award	$0	+4,426	+109%	$0.000000	8,491	22 Jan 2026	Common Stock	4,426,000		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Series A Convertible Preferred Stock is convertible at any time at the option of the holder into Common Stock on a one-for-one thousand basis.
F2	The shares of Series A Convertible Preferred Stock were issued to Dr. Trieu as compensation pursuant to the accomplishment of performance milestones under a Restricted Stock Agreement dated January 21, 2026.